Short Bowel Syndrome (SBS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Short Bowel Syndrome (SBS) Market Outlook
Thelansis’s “Short Bowel Syndrome
(SBS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Short Bowel Syndrome (SBS) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Short
Bowel Syndrome (SBS) Overview
Short
bowel syndrome (SBS) is a condition marked by reduced digestive and absorptive
capabilities, often stemming from surgical removal, congenital defects, or
bowel diseases. This absorption deficiency leads to nutritional and electrolyte
imbalances. In adults, SBS is typically defined as having less than 180 to 200
centimeters of remaining small bowel (in contrast to the normal range of 275 to
850 cm), necessitating nutritional and fluid supplementation. Patients exhibit
malabsorption-related symptoms like weight loss, diarrhea, steatorrhea,
dehydration, malnutrition, and electrolyte disturbances. SBS is an uncommon
malabsorptive disorder primarily caused by extensive surgical small intestine
resection, resulting in significant morbidity, mortality, and a reduced quality
of life. Parenteral nutrition is generally unnecessary for those with over 180
cm of small bowel. Those with over 90 cm may require it for less than a year,
while those with less than 60 cm will likely need lifelong parenteral nutrition.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment